This brief analyzes payment negotiation outcomes between insurers and providers from the independent dispute resolution process under the No Surprises Act.| Peterson-KFF Health System Tracker
On average, the new Medicare negotiated drug prices are 2.8 times the average of drug prices in 11 OECD countries of similar size and wealth.| Peterson-KFF Health System Tracker
This analysis uses the Merative MarketScan 2022 commercial claims to estimate the number of enrollees in the employer-sponsored insurance market who use one or more of the ten drugs selected for Medicare Part D price negotiations.| Peterson-KFF Health System Tracker
Drugs solely approved to treat obesity have minimal to no coverage on most ACA Marketplace plans. Wegovy, a semaglutide approved for weight loss, is included in just 1% of Marketplace plans, while Ozempic, which has the same active ingredient but is approved for diabetes treatment and sometimes used off-label for weight loss, is included in 82% of Marketplace plan formularies. Among ACA Marketplace plans with these drugs on formulary, prior authorization is required by most plans. All plans ...| Peterson-KFF Health System Tracker
People with medical debt are more likely to have other forms of financial distress than other people including loans, overdrawn accounts, and few savings.| Peterson-KFF Health System Tracker
Although most adults are in good health and have health insurance, more than 1 in 4 adults (28%) reported delaying or foregoing healthcare due to cost.| Peterson-KFF Health System Tracker